Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.

Kramer VG, Varsaneux O, Oliviera M, Colby-Germinario SP, Mesplède T, Wainberg MA.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):7-14. doi: 10.1097/QAI.0000000000000223.

PMID:
24872133
2.

Baseline susceptibility of primary HIV-2 to entry inhibitors.

Borrego P, Calado R, Marcelino JM, Bártolo I, Rocha C, Cavaco-Silva P, Doroana M, Antunes F, Maltez F, Caixas U, Barroso H, Taveira N.

Antivir Ther. 2012;17(3):565-70. doi: 10.3851/IMP1996. Epub 2012 Jan 25.

PMID:
22293827
3.

Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.

Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, Tressler R, Sloan RD, Wainberg MA.

Antimicrob Agents Chemother. 2012 Aug;56(8):4154-60. doi: 10.1128/AAC.00409-12. Epub 2012 May 21.

4.

HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.

Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J.

AIDS. 2007 Mar 30;21(6):693-702.

PMID:
17413690
5.

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M.

J Virol. 2007 Mar;81(5):2359-71. Epub 2006 Dec 20.

6.

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.

Roche M, Jakobsen MR, Ellett A, Salimiseyedabad H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR.

Retrovirology. 2011 Nov 7;8:89. doi: 10.1186/1742-4690-8-89.

7.

Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N.

Antimicrob Agents Chemother. 2013 May;57(5):2076-86. doi: 10.1128/AAC.02588-12. Epub 2013 Feb 12.

8.

Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.

Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, Robinson J, Burton DR, Bell J, Simmonds P, Ball J, Clapham PR.

Retrovirology. 2008 Jan 18;5:5. doi: 10.1186/1742-4690-5-5.

9.

Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization.

Boonchawalit S, Harada S, Shirai N, Gatanaga H, Oka S, Matsushita S, Yoshimura K.

Jpn J Infect Dis. 2016 May 20;69(3):236-43. doi: 10.7883/yoken.JJID.2015.310. Epub 2015 Jul 10.

10.

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A.

J Virol. 2005 Jul;79(13):8454-69.

11.

Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.

Revilla A, Delgado E, Christian EC, Dalrymple J, Vega Y, Carrera C, González-Galeano M, Ocampo A, de Castro RO, Lezaún MJ, Rodríguez R, Mariño A, Ordóñez P, Cilla G, Cisterna R, Santamaría JM, Prieto S, Rakhmanova A, Vinogradova A, Ríos M, Pérez-Álvarez L, Nájera R, Montefiori DC, Seaman MS, Thomson MM.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):889-901. doi: 10.1089/AID.2010.0177. Epub 2011 Feb 16.

PMID:
21226626
12.

Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.

Zhou N, Fan L, Ho HT, Nowicka-Sans B, Sun Y, Zhu Y, Hu Y, McAuliffe B, Rose B, Fang H, Wang T, Kadow J, Krystal M, Alexander L, Colonno R, Lin PF.

Virology. 2010 Jul 5;402(2):256-61. doi: 10.1016/j.virol.2010.03.033. Epub 2010 Apr 18.

13.

Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.

Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, Siripanyaphinyo U, Wichukchinda N, Tokunaga K, Yasunaga T, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M.

Microbes Infect. 2009 Mar;11(3):334-43. doi: 10.1016/j.micinf.2008.12.008. Epub 2008 Dec 27.

PMID:
19136072
14.

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.

Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW.

J Virol. 2010 Oct;84(20):10863-76. doi: 10.1128/JVI.01109-10. Epub 2010 Aug 11.

15.
16.

Antigenic properties of the HIV envelope on virions in solution.

Ray K, Mengistu M, Yu L, Lewis GK, Lakowicz JR, DeVico AL.

J Virol. 2014 Feb;88(3):1795-808. doi: 10.1128/JVI.03048-13. Epub 2013 Nov 27. Erratum in: J Virol. 2014 May;88(10):5901. Yu, Lei [added].

17.

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR.

Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43.

18.

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96.

19.

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H.

J Virol. 2007 Aug;81(16):8533-42. Epub 2007 May 23.

20.

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.

Supplemental Content

Support Center